NBIX News and Press, Neurocrine Biosciences Inc. From 08/05/22

Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NBIX) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Rober...

Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment of US$30 million to Sosei Heptares from Neurocrine NBI-1117568 is the m...

Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q2 Non-GAAP EPS of $0.84 misses by $0.05 . Revenue of $378.2M (+30.9% Y/Y) beats by $34.75M . INGREZZA (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion For further de...

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $350 Million INGREZZA ® (valbenazine) 2022 Net Prod...

SMID cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings in...

The second quarter results will be reported on Tuesday, July 26th, and will reflect the first revenue stream for two newly approved drugs. I will share with the reader what we should look for as it relates to future growth and remaining within the restraints of a proper spending budge...

Neurocrine should soon release Phase II data on NBI-827104, and a positive read-out on a largely overlooked drug today could add 5% to 10% to NBIX's fair value. Between the expansion of the sales force and new marketing initiatives, Neurocrine is looking to reignite sales momentum in ...

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 4 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Neurocrine Bioscien...

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 PR Newswire - Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents...